Recent Investment Analysts’ Ratings Changes for Eupraxia Pharmaceuticals (EPRX)

Several analysts have recently updated their ratings and price targets for Eupraxia Pharmaceuticals (NASDAQ: EPRX):

• 10/8/2026 – Eupraxia Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/1/2026 – Eupraxia Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
• 9/24/2026 – Eupraxia Pharmaceuticals was given a new $25.00 price target by Stifel Nicolaus.
• 9/24/2026 – Eupraxia Pharmaceuticals is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
• 9/12/2026 – Eupraxia Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.

Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee.